rabeprazole 10 mg and 20 mg tablet (Pariet®)
Eisai Ltd (No. 232/06)

Product Update

6 January 2006

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

Rabeprazole 10 mg and 20 mg tablet (Pariet®) is accepted for use within NHS Scotland for the treatment of Zollinger-Ellison syndrome.

Other proton pump inhibitors are available for this indication at a lower cost per treatment period.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 16 November 2005.

Chairman
Scottish Medicines Consortium

Secretariat - Delta House 50 West Nile Street Glasgow G1 2NP
Telephone 0141 225 6989
E-mail: Rosie.Murray@nhshealthquality.org

Chairman Professor David Webb